Summary
Global Markets Direct’s, ‘Osteoporosis - Pipeline Review, H1 2016’, provides an overview of the Osteoporosis pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Osteoporosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Osteoporosis and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Osteoporosis
- The report reviews pipeline therapeutics for Osteoporosis by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Osteoporosis therapeutics and enlists all their major and minor projects
- The report assesses Osteoporosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Osteoporosis
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Osteoporosis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Osteoporosis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
Alethia Biotherapeutics Inc.
Alize Pharma SAS
Alkem Laboratories Ltd.
AlphaMab Co., Ltd
Amgen Inc.
Amura Holdings Limited
Arcarios BV
BiologicsMD, Inc.
Bone Medical Limited
Bone Therapeutics SA
Caladrius Biosciences, Inc.
Chugai Pharmaceutical Co., Ltd.
Clonz Biotech Private Limited
Corium International, Inc.
Critical Pharmaceuticals Limited
Daiichi Sankyo Company, Limited
ElexoPharm GmbH
Eli Lilly and Company
EndoCeutics, Inc.
Enteris BioPharma, Inc.
Enzo Biochem, Inc.
Gador S.A.
Galapagos NV
Glide Pharmaceutical Technologies Limited
Hanmi Pharmaceuticals, Co. Ltd.
Haoma Medica Ltd.
Immunovo BV
Kaken Pharmaceutical Co., Ltd.
Korea Kolmar Co. Ltd.
Ligand Pharmaceuticals, Inc.
Lotus Pharmaceutical Co., Ltd.
Merck & Co., Inc.
Mereo Biopharma Group Limited
Mithra Pharmaceuticals S.A.
Novartis AG
Omeros Corporation
Oncobiologics, Inc.
Oscotec Inc.
Osteologix Holdings Plc.
Paras Biopharmaceuticals Finland Oy
PhytoHealth Corporation
R-Pharm
Radius Health, Inc.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Shin Poong Pharm.Co., Ltd.
Sinil Pharmaceutical Co., Ltd
STELIS Biopharma Pvt. Ltd.
Sumitomo Dainippon Pharma Co., Ltd.
TAmiRNA GmbH
TechnoPhage SA
Terpenoid Therapeutics, Inc.
TSH Biopharm Corporation Limited
Uni-Bio Science Group Ltd.
Wroclawskie Centrum Badan EIT+ Sp. z o.o.
Yooyoung Pharmaceutical Co., Ltd.
Zosano Pharma Corporation
Zydus Cadila Healthcare Limited
'
Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Osteoporosis Overview 11
Therapeutics Development 12
Pipeline Products for Osteoporosis - Overview 12
Pipeline Products for Osteoporosis - Comparative Analysis 13
Osteoporosis - Therapeutics under Development by Companies 14
Osteoporosis - Therapeutics under Investigation by Universities/Institutes 20
Osteoporosis - Pipeline Products Glance 21
Late Stage Products 21
Clinical Stage Products 22
Early Stage Products 23
Unknown Stage Products 24
Osteoporosis - Products under Development by Companies 25
Osteoporosis - Products under Investigation by Universities/Institutes 31
Osteoporosis - Companies Involved in Therapeutics Development 32
Alethia Biotherapeutics Inc. 32
Alize Pharma SAS 33
Alkem Laboratories Ltd. 34
AlphaMab Co., Ltd 35
Amgen Inc. 36
Amura Holdings Limited 37
Arcarios BV 38
BiologicsMD, Inc. 39
Bone Medical Limited 40
Bone Therapeutics SA 41
Caladrius Biosciences, Inc. 42
Chugai Pharmaceutical Co., Ltd. 43
Clonz Biotech Private Limited 44
Corium International, Inc. 45
Critical Pharmaceuticals Limited 46
Daiichi Sankyo Company, Limited 47
ElexoPharm GmbH 48
Eli Lilly and Company 49
EndoCeutics, Inc. 50
Enteris BioPharma, Inc. 51
Enzo Biochem, Inc. 52
Gador S.A. 53
Galapagos NV 54
Glide Pharmaceutical Technologies Limited 55
Hanmi Pharmaceuticals, Co. Ltd. 56
Haoma Medica Ltd. 57
Immunovo BV 58
Kaken Pharmaceutical Co., Ltd. 59
Korea Kolmar Co. Ltd. 60
Ligand Pharmaceuticals, Inc. 61
Lotus Pharmaceutical Co., Ltd. 62
Merck & Co., Inc. 63
Mereo Biopharma Group Limited 64
Mithra Pharmaceuticals S.A. 65
Novartis AG 66
Omeros Corporation 67
Oncobiologics, Inc. 68
Oscotec Inc. 69
Osteologix Holdings Plc. 70
Paras Biopharmaceuticals Finland Oy 71
PhytoHealth Corporation 72
R-Pharm 73
Radius Health, Inc. 74
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. 75
Shin Poong Pharm.Co., Ltd. 76
Sinil Pharmaceutical Co., Ltd 77
STELIS Biopharma Pvt. Ltd. 78
Sumitomo Dainippon Pharma Co., Ltd. 79
TAmiRNA GmbH 80
TechnoPhage SA 81
Terpenoid Therapeutics, Inc. 82
TSH Biopharm Corporation Limited 83
Uni-Bio Science Group Ltd. 84
Wroclawskie Centrum Badan EIT+ Sp. z o.o. 85
Yooyoung Pharmaceutical Co., Ltd. 86
Zosano Pharma Corporation 87
Zydus Cadila Healthcare Limited 88
Osteoporosis - Therapeutics Assessment 89
Assessment by Monotherapy Products 89
Assessment by Combination Products 90
Assessment by Target 91
Assessment by Mechanism of Action 94
Assessment by Route of Administration 97
Assessment by Molecule Type 99
Drug Profiles 101
(acolbifene hydrochloride + prasterone) - Drug Profile 101
2-AMD - Drug Profile 102
2-GES - Drug Profile 103
3D-QM - Drug Profile 104
3D-QMS - Drug Profile 105
AB-25E9 - Drug Profile 106
abaloparatide - Drug Profile 107
alendronate sodium - Drug Profile 111
AM-3701 - Drug Profile 112
ARC-205 - Drug Profile 113
blosozumab - Drug Profile 114
BMD-1111 - Drug Profile 115
BN-005 - Drug Profile 117
BN-008 - Drug Profile 118
BPS-804 - Drug Profile 119
calcitonin - Drug Profile 121
CDR-914K058 - Drug Profile 124
CDRI-99/373 - Drug Profile 125
CH-5036249 - Drug Profile 127
denosumab - Drug Profile 128
denosumab biosimilar - Drug Profile 131
denosumab biosimilar - Drug Profile 132
denosumab biosimilar - Drug Profile 133
DPF-020 - Drug Profile 134
Drug to Inhibit miR-31 for Osteoporosis - Drug Profile 135
Drug to Target miR-002 for Osteoporosis - Drug Profile 136
Drugs for Postmenopausal Osteoporosis - Drug Profile 137
Drugs to Modulate PPAR-Delta for Immunology, Metabolic and Musculoskeletal Disorders - Drug Profile 138
DS-1501 - Drug Profile 139
eldecalcitol - Drug Profile 140
Estetrol - Drug Profile 141
Eu-232 - Drug Profile 143
Ewha-18278 - Drug Profile 144
genipin - Drug Profile 145
HCP-1405 - Drug Profile 146
IG-8801 - Drug Profile 147
IHBD-1 - Drug Profile 148
KAL-671 - Drug Profile 149
KKM-0805 - Drug Profile 150
KKM-0902 - Drug Profile 151
KN-012 - Drug Profile 152
lasofoxifene tartrate - Drug Profile 153
MAb-7 - Drug Profile 155
Monoclonal Antibody to Inhibit Sclerostin for Osteoporosis - Drug Profile 156
MOR-106 - Drug Profile 157
NBS-101 - Drug Profile 159
NEP-28 - Drug Profile 161
OCT-1547 - Drug Profile 162
odanacatib - Drug Profile 163
ODS-656 - Drug Profile 166
Oratonin - Drug Profile 167
OXY-149 - Drug Profile 168
PHN-031 - Drug Profile 170
poncirin - Drug Profile 171
PREOB - Drug Profile 172
Proteins to Inhibit RANKL for Oncology and Osteoporosis - Drug Profile 173
R-Spondin 1 - Drug Profile 174
Recombinant Protein 1 for Rheumatoid Arthritis and Osteoporosis - Drug Profile 175
Recombinant Protein 2 for Rheumatoid Arthritis and Osteoporosis - Drug Profile 176
Recombinant Protein 3 for Rheumatoid Arthritis and Osteoporosis - Drug Profile 177
Recombinant Protein for Osteoporosis - Drug Profile 178
Recombinant Protein to Agonize PTH Receptor for Osteoporosis and Osteoarthritis - Drug Profile 179
Recombinant Protein to Inhibit Activin A for Osteoporosis and Cancer Cachexia - Drug Profile 180
Recombinant Protein to Inhibit Serine Protease for Bone Disorders and Osteoporosis - Drug Profile 181
romosozumab - Drug Profile 182
RPH-203 - Drug Profile 184
S-0071500 - Drug Profile 185
S-101479 - Drug Profile 186
S-49288 - Drug Profile 187
SI-000513 - Drug Profile 188
Small Molecule to Agonize LRP for Osteoporosis - Drug Profile 189
Small Molecule to Agonize PTH-1R for Osteoporosis - Drug Profile 190
Small Molecule to Inhibit 17beta-HSD2 for Osteoporosis - Drug Profile 191
Small Molecule to Target LGR4 for Oncology and Osteoporosis - Drug Profile 192
Small Molecule to Target OGR1 for Oncology, Bone Diseases, Asthma and Osteoporosis - Drug Profile 193
Small Molecules for Immunology, Metabolic and Musculoskeletal Disorders - Drug Profile 194
Small Molecules for Immunology, Musculoskeletal and Metabolic Disorders - Drug Profile 195
Small Molecules for Osteopenia and Osteoporosis - Drug Profile 196
Small Molecules for Osteoporosis - Drug Profile 197
Small Molecules for Osteoporosis - Drug Profile 198
Small Molecules for Primary Juvenile Osteoporosis - Drug Profile 200
Small Molecules to Agonize Androgen Receptor for Osteoporosis - Drug Profile 201
Small Molecules to Agonize Glucocorticoid Receptor for Osteoporosis - Drug Profile 202
Small Molecules to Inhibit 17Beta-HSD2 for Osteoporosis - Drug Profile 203
Small Molecules to Inhibit GGDPS for Cancer and Bone Metastasis - Drug Profile 204
Small Molecules to Inhibit Kinase for Osteoarthritis and Osteoporosis - Drug Profile 205
Small Molecules to Inhibit NO Synthase for Toxicology, Metabolic and Dermatology - Drug Profile 206
Small Molecules to Inhibit Src Tyrosine Kinase for Oncology, Cardiovascular and Metabolic Disorders - Drug Profile 207
Sodium Quinate - Drug Profile 208
SP-35454 - Drug Profile 209
SR-2595 - Drug Profile 210
Stem Cell Therapy for Osteoporosis and Periodontitis - Drug Profile 211
Synthetic Peptide for Osteoporosis - Drug Profile 212
Synthetic Peptide for Osteoporosis and Bone Fracture - Drug Profile 213
T-2GES - Drug Profile 214
teriparatide - Drug Profile 215
teriparatide - Drug Profile 217
teriparatide - Drug Profile 218
teriparatide - Drug Profile 219
teriparatide - Drug Profile 220
teriparatide - Drug Profile 221
teriparatide acetate - Drug Profile 222
teriparatide biosimilar - Drug Profile 223
teriparatide biosimilar - Drug Profile 224
teriparatide biosimilar - Drug Profile 225
teriparatide biosimilar - Drug Profile 226
TZ-121 - Drug Profile 227
Vaccine to Target Sclerostin for Osteoporosis - Drug Profile 228
VS-105 - Drug Profile 229
zoledronic acid - Drug Profile 230
Osteoporosis - Recent Pipeline Updates 232
Osteoporosis - Dormant Projects 256
Osteoporosis - Discontinued Products 267
Osteoporosis - Product Development Milestones 269
Featured News & Press Releases 269
Appendix 278
Methodology 278
Coverage 278
Secondary Research 278
Primary Research 278
Expert Panel Validation 278
Contact Us 278
Disclaimer 279
List of Tables
Number of Products under Development for Osteoporosis, H1 2016 20
Number of Products under Development for Osteoporosis - Comparative Analysis, H1 2016 21
Number of Products under Development by Companies, H1 2016 23
Number of Products under Development by Companies, H1 2016 (Contd..1) 24
Number of Products under Development by Companies, H1 2016 (Contd..2) 25
Number of Products under Development by Companies, H1 2016 (Contd..3) 26
Number of Products under Development by Companies, H1 2016 (Contd..4) 27
Number of Products under Investigation by Universities/Institutes, H1 2016 28
Comparative Analysis by Late Stage Development, H1 2016 29
Comparative Analysis by Clinical Stage Development, H1 2016 30
Comparative Analysis by Early Stage Development, H1 2016 31
Comparative Analysis by Unknown Stage Development, H1 2016 32
Products under Development by Companies, H1 2016 33
Products under Development by Companies, H1 2016 (Contd..1) 34
Products under Development by Companies, H1 2016 (Contd..2) 35
Products under Development by Companies, H1 2016 (Contd..3) 36
Products under Development by Companies, H1 2016 (Contd..4) 37
Products under Development by Companies, H1 2016 (Contd..5) 38
Products under Investigation by Universities/Institutes, H1 2016 39
Osteoporosis - Pipeline by Alethia Biotherapeutics Inc., H1 2016 40
Osteoporosis - Pipeline by Alize Pharma SAS, H1 2016 41
Osteoporosis - Pipeline by Alkem Laboratories Ltd., H1 2016 42
Osteoporosis - Pipeline by AlphaMab Co., Ltd, H1 2016 43
Osteoporosis - Pipeline by Amgen Inc., H1 2016 44
Osteoporosis - Pipeline by Amura Holdings Limited, H1 2016 45
Osteoporosis - Pipeline by Arcarios BV, H1 2016 46
Osteoporosis - Pipeline by BiologicsMD, Inc., H1 2016 47
Osteoporosis - Pipeline by Bone Medical Limited, H1 2016 48
Osteoporosis - Pipeline by Bone Therapeutics SA, H1 2016 49
Osteoporosis - Pipeline by Caladrius Biosciences, Inc. , H1 2016 50
Osteoporosis - Pipeline by Chugai Pharmaceutical Co., Ltd., H1 2016 51
Osteoporosis - Pipeline by Clonz Biotech Private Limited, H1 2016 52
Osteoporosis - Pipeline by Corium International, Inc., H1 2016 53
Osteoporosis - Pipeline by Critical Pharmaceuticals Limited, H1 2016 54
Osteoporosis - Pipeline by Daiichi Sankyo Company, Limited, H1 2016 55
Osteoporosis - Pipeline by ElexoPharm GmbH, H1 2016 56
Osteoporosis - Pipeline by Eli Lilly and Company, H1 2016 57
Osteoporosis - Pipeline by EndoCeutics, Inc., H1 2016 58
Osteoporosis - Pipeline by Enteris BioPharma, Inc., H1 2016 59
Osteoporosis - Pipeline by Enzo Biochem, Inc., H1 2016 60
Osteoporosis - Pipeline by Gador S.A., H1 2016 61
Osteoporosis - Pipeline by Galapagos NV, H1 2016 62
Osteoporosis - Pipeline by Glide Pharmaceutical Technologies Limited, H1 2016 63
Osteoporosis - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2016 64
Osteoporosis - Pipeline by Haoma Medica Ltd., H1 2016 65
Osteoporosis - Pipeline by Immunovo BV, H1 2016 66
Osteoporosis - Pipeline by Kaken Pharmaceutical Co., Ltd., H1 2016 67
Osteoporosis - Pipeline by Korea Kolmar Co. Ltd., H1 2016 68
Osteoporosis - Pipeline by Ligand Pharmaceuticals, Inc., H1 2016 69
Osteoporosis - Pipeline by Lotus Pharmaceutical Co., Ltd., H1 2016 70
Osteoporosis - Pipeline by Merck & Co., Inc., H1 2016 71
Osteoporosis - Pipeline by Mereo Biopharma Group Limited, H1 2016 72
Osteoporosis - Pipeline by Mithra Pharmaceuticals S.A., H1 2016 73
Osteoporosis - Pipeline by Novartis AG, H1 2016 74
Osteoporosis - Pipeline by Omeros Corporation, H1 2016 75
Osteoporosis - Pipeline by Oncobiologics, Inc., H1 2016 76
Osteoporosis - Pipeline by Oscotec Inc., H1 2016 77
Osteoporosis - Pipeline by Osteologix Holdings Plc., H1 2016 78
Osteoporosis - Pipeline by Paras Biopharmaceuticals Finland Oy, H1 2016 79
Osteoporosis - Pipeline by PhytoHealth Corporation, H1 2016 80
Osteoporosis - Pipeline by R-Pharm, H1 2016 81
Osteoporosis - Pipeline by Radius Health, Inc., H1 2016 82
Osteoporosis - Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., H1 2016 83
Osteoporosis - Pipeline by Shin Poong Pharm.Co., Ltd., H1 2016 84
Osteoporosis - Pipeline by Sinil Pharmaceutical Co., Ltd, H1 2016 85
Osteoporosis - Pipeline by STELIS Biopharma Pvt. Ltd., H1 2016 86
Osteoporosis - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2016 87
Osteoporosis - Pipeline by TAmiRNA GmbH, H1 2016 88
Osteoporosis - Pipeline by TechnoPhage SA, H1 2016 89
Osteoporosis - Pipeline by Terpenoid Therapeutics, Inc., H1 2016 90
Osteoporosis - Pipeline by TSH Biopharm Corporation Limited, H1 2016 91
Osteoporosis - Pipeline by Uni-Bio Science Group Ltd., H1 2016 92
Osteoporosis - Pipeline by Wroclawskie Centrum Badan EIT+ Sp. z o.o., H1 2016 93
Osteoporosis - Pipeline by Yooyoung Pharmaceutical Co., Ltd., H1 2016 94
Osteoporosis - Pipeline by Zosano Pharma Corporation, H1 2016 95
Osteoporosis - Pipeline by Zydus Cadila Healthcare Limited, H1 2016 96
Assessment by Monotherapy Products, H1 2016 97
Assessment by Combination Products, H1 2016 98
Number of Products by Stage and Target, H1 2016 100
Number of Products by Stage and Mechanism of Action, H1 2016 103
Number of Products by Stage and Route of Administration, H1 2016 106
Number of Products by Stage and Molecule Type, H1 2016 108
Osteoporosis Therapeutics - Recent Pipeline Updates, H1 2016 240
Osteoporosis - Dormant Projects, H1 2016 264
Osteoporosis - Dormant Projects (Contd..1), H1 2016 265
Osteoporosis - Dormant Projects (Contd..2), H1 2016 266
Osteoporosis - Dormant Projects (Contd..3), H1 2016 267
Osteoporosis - Dormant Projects (Contd..4), H1 2016 268
Osteoporosis - Dormant Projects (Contd..5), H1 2016 269
Osteoporosis - Dormant Projects (Contd..6), H1 2016 270
Osteoporosis - Dormant Projects (Contd..7), H1 2016 271
Osteoporosis - Dormant Projects (Contd..8), H1 2016 272
Osteoporosis - Dormant Projects (Contd..9), H1 2016 273
Osteoporosis - Dormant Projects (Contd..10), H1 2016 274
Osteoporosis - Discontinued Products, H1 2016 275
Osteoporosis - Discontinued Products (Contd..1), H1 2016 276
List of Figures
Number of Products under Development for Osteoporosis, H1 2016 20
Number of Products under Development for Osteoporosis - Comparative Analysis, H1 2016 21
Number of Products under Development by Companies, H1 2016 22
Number of Products under Investigation by Universities/Institutes, H1 2016 28
Comparative Analysis by Late Stage Development, H1 2016 29
Comparative Analysis by Clinical Stage Development, H1 2016 30
Comparative Analysis by Early Stage Products, H1 2016 31
Assessment by Monotherapy Products, H1 2016 97
Number of Products by Top 10 Targets, H1 2016 99
Number of Products by Stage and Top 10 Targets, H1 2016 99
Number of Products by Top 10 Mechanism of Actions, H1 2016 102
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 102
Number of Products by Top 10 Routes of Administration, H1 2016 105
Number of Products by Stage and Top 10 Routes of Administration, H1 2016 105
Number of Products by Top 10 Molecule Types, H1 2016 107
Number of Products by Stage and Top 10 Molecule Types, H1 2016 107
